Denosumab (Prolia®) is a fully human IgG2 monoclonal antibody inhibiting the RANK ligand which is an essential factor for the formation, activation and survival of osteoclasts. It is used for the treatment of osterporosis.

PPS has generated considerable experience in the analysis of different originator batches as well as variants of biosimilars of Denosumab.

We have established an analytical program according to the ICH Q6B guidance, including the method setup, validation of customer specific methods and release testing.

This package includes different assays for protein quantification and characterizing the protein primary structure and secondary structure, as well as detailed analysis of N-glycosylation and protein modification

 

Your contact for Denosumab at Protagen Protein Services GmbH

Martin-Blueggel 150x100px

Martin Blüggel

Chief Executive Officer (CEO)
Our business development team will be happy to assist you with your project.

Phone: +49 (0) 231 9742-6100
Email: salesproteinservices@ProtagenProteinServices.com